Christ Hospital

Cardiac Dimensions Appoints Satya Shreenivas, MD as Chief Medical Officer

Retrieved on: 
Tuesday, January 16, 2024
Health, Medical Devices, Cardiology, Medpace, Patient, FMR, Tricuspid valve, MD, Multimedia, EMPOWER, Medical director, University, Heart failure, Cardiac catheterization, The Christ Hospital, MBA, Dimension, Christ Hospital, Mitral regurgitation, Medical device

Cardiac Dimensions ®, a leader in the development of innovative and minimally invasive treatment modalities to address patients suffering from heart failure with functional mitral regurgitation (FMR), today announced that renowned interventional cardiologist Satya Shreenivas, MD, MBA has joined the company as Chief Medical Officer.

Key Points: 
  • Cardiac Dimensions ®, a leader in the development of innovative and minimally invasive treatment modalities to address patients suffering from heart failure with functional mitral regurgitation (FMR), today announced that renowned interventional cardiologist Satya Shreenivas, MD, MBA has joined the company as Chief Medical Officer.
  • View the full release here: https://www.businesswire.com/news/home/20240116766817/en/
    Cardiac Dimensions' new Chief Medical Officer Satya Shreenivas, MD, MBA (Photo: Business Wire)
    Dr. Shreenivas brings his rich experience in both the clinical and commercial aspects of the structural heart landscape to his new role with Cardiac Dimensions.
  • His industry roles have included serving as Chief Medical Officer for HLT Medical, a transcatheter heart valve company, as Chief of Cardiology with Optum/United Health subsidiary SCA Health, and as Medical Director for clinical research organization Medpace.
  • Dr. Shreenivas has been instrumental in advising Cardiac Dimensions on its EMPOWER Trial of the Carillon Mitral Contour System®.

HUDSON REGIONAL HOSPITAL AND CAREPOINT HEALTH CREATE NEW HEALTHCARE SYSTEM TO SERVE HUDSON COUNTY

Retrieved on: 
Friday, January 12, 2024
Health, Patient, Hospital, Medicaid, Health care, Partnership, Insurance, Documentation, Hoboken University Medical Center, Bayonne Medical Center, Safety, Hudson Regional Hospital, CMS, System, Letter, Christ Hospital, Physician

JERSEY CITY, N.J., Jan. 12, 2024 /PRNewswire/ -- Executive leadership at both Hudson Regional Hospital and CarePoint Health System are announcing the creation of Hudson Health System, a new management company that will incorporate the acute care facilities of Hudson Regional Hospital and CarePoint Health.

Key Points: 
  • JERSEY CITY, N.J., Jan. 12, 2024 /PRNewswire/ -- Executive leadership at both Hudson Regional Hospital and CarePoint Health System are announcing the creation of Hudson Health System, a new management company that will incorporate the acute care facilities of Hudson Regional Hospital and CarePoint Health.
  • Hudson Health System will be a four-hospital network including Hudson Regional Hospital, Bayonne Medical Center, Hoboken University Medical Center, and Christ Hospital in Jersey City.
  • The new system will continue both Hudson Regional Hospital's and CarePoint Health's demonstrated commitment to providing high-quality, affordable healthcare for local residents.
  • SUPPORT FOR HUDSON HEALTH SYSTEM FROM HUDSON COUNTY ELECTED OFFICIALS:
    Jersey City Mayor Steven Fulop:
    "It became clear over the last several months that Hudson County had an opportunity to create a dynamic new healthcare model.

PMcardio Launches Certified AI-Powered Solution that Outperforms Doctors in Heart Attack Detection

Retrieved on: 
Thursday, November 23, 2023
Atrium Health, Database, Queen, ECG, Woman, Physician, Medicine, FDA, Hospital, Splenic infarction, Death, Atrium, Chest pain, Patient, Diagnosis, Facial muscles, Christ Hospital, Medical device

This pioneering AI-powered clinical assistant is now the first certified solution proven to outperform doctors in detecting heart attacks.

Key Points: 
  • This pioneering AI-powered clinical assistant is now the first certified solution proven to outperform doctors in detecting heart attacks.
  • Traditional diagnostic methods, focused on the STEMI/NSTEMI criteria, miss about 30% of acute heart attack patients, highlighting the need for more accurate and prompt detection.
  • With over 2,500 hospitals on the waiting list, PMcardio is on track to transform heart attack diagnosis on a global scale.
  • This development is set to have a widespread impact, fundamentally transforming the approach to heart attack diagnosis and treatment around the globe.

CarePoint Health Celebrates 150th Anniversary of Christ Hospital With Inaugural Gala Event

Retrieved on: 
Friday, November 10, 2023
Well, Medicaid, Health equity, History, Patient, Master of Surgery, Marketing, 150th anniversary of Canada, Council, Health, Assembly, Christ Hospital, MBA, MD, African Americans, Hospital, Hudson House, Management

Jersey City, NJ, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Celebrating the historic 150th Anniversary of Christ Hospital, CarePoint Health and its newly-launched Just Health Foundation held a gala event last Thursday night in Jersey City that was attended by over 300 supporters of the nonprofit health system.

Key Points: 
  • Jersey City, NJ, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Celebrating the historic 150th Anniversary of Christ Hospital, CarePoint Health and its newly-launched Just Health Foundation held a gala event last Thursday night in Jersey City that was attended by over 300 supporters of the nonprofit health system.
  • The event was led by Marie Duffy, Christ Hospital’s Chief Hospital Executive and Justin Drew, Vice President: Marketing, Strategy & Patient Experience.
  • Mayor Fulop was joined by Council President Joyce Watterman and Council members Rich Boggiano and Yusef Saleh to present a municipal proclamation congratulating Christ Hospital on its 150th anniversary.
  • In 2021, Christ Hospital was ranked #1 in the nation as the most socially responsible hospital.

NRC Health unveils winners of 2023 patient experience and loyalty awards

Retrieved on: 
Tuesday, August 8, 2023
New England Aquarium, New England, Success, Marital status, Mayo Clinic Hospital (Rochester), University, Beth Israel Deaconess Medical Center, National Research Corporation, Patient experience, NRC, Hospital, Health, Human, Sea, Organization, NPS, Hospital of the University of Pennsylvania, Missouri Baptist Medical Center, Community hospital, Monterey Peninsula, UC, The Christ Hospital, UC Davis Health Stadium, Patient, Lahey Hospital & Medical Center, California Hospital Medical Center, Christ Hospital, Parkview Health, Pharmaceutical industry, Nursing, Mercy, Troy

LINCOLN, Neb., Aug. 08, 2023 (GLOBE NEWSWIRE) -- NRC Health , a leading provider of Human Understanding® and data-driven insights, is pleased to announce the recipients of the 2023 Consumer Loyalty Awards and the Excellence in Patient Experience Awards.

Key Points: 
  • LINCOLN, Neb., Aug. 08, 2023 (GLOBE NEWSWIRE) -- NRC Health , a leading provider of Human Understanding® and data-driven insights, is pleased to announce the recipients of the 2023 Consumer Loyalty Awards and the Excellence in Patient Experience Awards.
  • NRC Health's Consumer Loyalty Award winners lead the way in delivering exceptional patient experiences.
  • Elevating the patient experience remains a priority in healthcare, and NRC Health's 2023 Excellence in Patient Experience Award winners have demonstrated outstanding commitment to individualized and human-centered care.
  • To check whether your local hospital is a 2023 honoree, see the full lists of winning organizations for both the 2023 Consumer Loyalty Awards and the 2023 Excellence in Patient Experience Awards .

NRC Health unveils winners of 2023 patient experience and loyalty awards

Retrieved on: 
Tuesday, August 8, 2023
New England Aquarium, New England, Success, Marital status, Mayo Clinic Hospital (Rochester), University, Beth Israel Deaconess Medical Center, National Research Corporation, Patient experience, NRC, Hospital, Health, Human, Sea, Organization, NPS, Hospital of the University of Pennsylvania, Missouri Baptist Medical Center, Community hospital, Monterey Peninsula, UC, The Christ Hospital, UC Davis Health Stadium, Patient, Lahey Hospital & Medical Center, California Hospital Medical Center, Christ Hospital, Parkview Health, Pharmaceutical industry, Nursing, Mercy, Troy

LINCOLN, Neb., Aug. 08, 2023 (GLOBE NEWSWIRE) -- NRC Health , a leading provider of Human Understanding® and data-driven insights, is pleased to announce the recipients of the 2023 Consumer Loyalty Awards and the Excellence in Patient Experience Awards.

Key Points: 
  • LINCOLN, Neb., Aug. 08, 2023 (GLOBE NEWSWIRE) -- NRC Health , a leading provider of Human Understanding® and data-driven insights, is pleased to announce the recipients of the 2023 Consumer Loyalty Awards and the Excellence in Patient Experience Awards.
  • NRC Health's Consumer Loyalty Award winners lead the way in delivering exceptional patient experiences.
  • Elevating the patient experience remains a priority in healthcare, and NRC Health's 2023 Excellence in Patient Experience Award winners have demonstrated outstanding commitment to individualized and human-centered care.
  • To check whether your local hospital is a 2023 honoree, see the full lists of winning organizations for both the 2023 Consumer Loyalty Awards and the 2023 Excellence in Patient Experience Awards .

Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis

Retrieved on: 
Tuesday, August 8, 2023
SAB, Ohio State University, Orchestra, Partnership, Institutional review board, HOPE, Virtue, FACC, ISR, Sirolimus, SABRE, Medicine, Angioplasty, Patient, Christ Hospital, IDE, Coronary artery disease, Principal, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Pharmaceutical industry, POBA, Terumo

“We believe that Virtue SAB has the potential to address a significant unmet clinical need and improve outcomes for a patient population with suboptimal treatment options.

Key Points: 
  • “We believe that Virtue SAB has the potential to address a significant unmet clinical need and improve outcomes for a patient population with suboptimal treatment options.
  • “This IDE approval and forthcoming pivotal study reflect our commitment to accelerating innovation through our differentiated, partnership-enabled business model.
  • The Virtue ISR-US pivotal study is a randomized, prospective, double-blind, multi-center, controlled study of Virtue SAB vs.
  • The conditional approval also requires the Company to submit additional information to the FDA.

Genetesis Receives 2nd FDA Breakthrough Device Designation for Non-Invasive Diagnosis of Myocardial Ischemia Using CardioFlux MCG

Retrieved on: 
Thursday, April 13, 2023
Technology, Medical Devices, General Health, Hospitals, Science, Clinical Trials, FDA, Cardiology, Biotechnology, Health, Health Technology, Research, Other Technology, Audio, Video, Biometrics, Other Health, Radiology, MCG, Partnership, CMD, Dipyridamole, Hospital, Anatomy, Moyamoya disease, Principal investigator, Perception, Cardiovascular disease, European Society of Cardiology, Disease, History, Ischemia, Medical director, The Christ Hospital, Patient, Investment, Christ Hospital, Diagnosis, Education, European Society for Medical Oncology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Breakthrough, Interventional cardiology, Food, Pharmaceutical industry, Medical device

Genetesis, Inc., the leader in biomagnetic cardiac imaging solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device designation for its flagship imaging solution, CardioFlux MCG, to identify myocardial ischemia in patients who may be suffering from coronary microvascular disease (CMD).

Key Points: 
  • Genetesis, Inc., the leader in biomagnetic cardiac imaging solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device designation for its flagship imaging solution, CardioFlux MCG, to identify myocardial ischemia in patients who may be suffering from coronary microvascular disease (CMD).
  • Annually, as many as 4 million patients in the United States alone are believed to present with diagnostic evidence of ischemia without evidence of obstructed coronary arteries, a condition broadly known as INOCA.
  • The FDA’s decision rested, in part, on the submission of preliminary findings from the MICRO trial, which attempted to demonstrate the use of non-invasive magnetocardiography (MCG) to diagnose myocardial ischemia in patients suspected to be suffering from CMD.
  • “Through various activities and investments, like our Women’s Heart Center, we’re making very real progress on that goal.

Neovasc Comments on New ICD-10-CM Diagnosis Codes for Refractory Angina

Retrieved on: 
Thursday, September 15, 2022
Hospital, Injury, Center, Incidence, TSX, Oxygen, Muscle tissue, Medicare, Adrenal insufficiency, Perfusion, Research, Blood, Patient, National, Carl, Centers for Medicare & Medicaid Services, Atherosclerosis, Diagnosis, NASDAQ, Christ Hospital, Heart, GLOBE, Union, Education, Piping and plumbing fitting, Artery, Angina, Disease, Society, Pharmaceutical industry

VANCOUVER and MINNEAPOLIS, Sept. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire Neovasc Inc. (Neovasc or the Company) (NASDAQ, TSX : NVCN ) today commented on the Centers for Medicare and Medicaid Services (CMS) development of new codes for the diagnosis and tracking of refractory angina.

Key Points: 
  • VANCOUVER and MINNEAPOLIS, Sept. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire Neovasc Inc. (Neovasc or the Company) (NASDAQ, TSX : NVCN ) today commented on the Centers for Medicare and Medicaid Services (CMS) development of new codes for the diagnosis and tracking of refractory angina.
  • The creation of new ICD-10-CM codes for refractory angina is an important step for patients and clinicians.
  • The primary new code, I20.2 Refractory Angina Pectoris, was supplemented with eight additional new codes describing refractory angina in combination with various conditions pertaining to atherosclerosis, or hardening of the hearts arteries.
  • Todays announcement is another important step forward for patients with refractory angina and for the Neovasc Reducer as an option for treating this disease, added Bill Little, Neovasc Chief Operating Officer.

Neovasc Announces Key Events at TCT 2022

Retrieved on: 
Thursday, September 8, 2022
Treatment, Piping and plumbing fitting, Chest pain, Muscle tissue, Convention center, Angina, Christ Hospital, NASDAQ, The Christ Hospital, Tel Aviv Sourasky Medical Center, Heart, Blood, Union, TSX, Innovation, Faculty, McMaster University, Boston Convention and Exhibition Center, GLOBE, Hospital, Company, Population, Perfusion, TCT, St. Francis Hospital, Adrenal insufficiency, Patient, Pharmaceutical industry, MD

VANCOUVER and MINNEAPOLIS, Sept. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire Neovasc Inc. (Neovasc or the Company) (NASDAQ, TSX : NVCN ) today announced its participation and presence at the Transcatheter Cardiovascular Therapeutics TCT 2022 conference (TCT), hosted by the Cardiovascular Research Foundation (CRF), taking place in person at the Boston Convention & Exhibition Center, September 16-19, 2022.

Key Points: 
  • VANCOUVER and MINNEAPOLIS, Sept. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire Neovasc Inc. (Neovasc or the Company) (NASDAQ, TSX : NVCN ) today announced its participation and presence at the Transcatheter Cardiovascular Therapeutics TCT 2022 conference (TCT), hosted by the Cardiovascular Research Foundation (CRF), taking place in person at the Boston Convention & Exhibition Center, September 16-19, 2022.
  • Members of the Neovasc team will be available at booth 647 in the exhibit hall.
  • For additional information and to register for TCT 2022, please visit: https://tct2022.crfconnect.com/ .
  • Neovasc is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular marketplace.